Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2026 04:41 ET | Source: Novo Nordisk A/S

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

New results from the landmark POSEIDON real-world evidence study at EAS Congress: 2 in 5 people with CVD have CV inflammation - higher risk of heart attack
May 13, 2026 08:00 ET | Source: Healthmap Solutions

Dr. Jonathan Gavras Joins Healthmap Solutions as Chief Medical Officer

Healthmap Solutions announces the appointment of Jonathan Gavras, MD, FCCP as Chief Medical Officer. Dr. Gavras will lead Healthmap’s clinical strategy.
April 15, 2026 13:11 ET | Source: AssureCKD

AssureCKD Appoints Former LumiraDx Technical Director Dr. Aman Khan as Chief Technology Officer to Lead Diagnostic Platform Development

AssureCKD has appointed Dr. Aman Khan as Chief Technology Officer to lead development of its MATLOC diagnostic platform for chronic kidney disease
March 17, 2026 07:00 ET | Source: R1 Therapeutics

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.
March 16, 2026 06:43 ET | Source: SNS Insider pvt ltd

Erythropoietin Drugs Market Size to Reach USD 18.45 Billion by 2035 Due to the Increasing Prevalence of Chronic Kidney Disease and Cancer-Related Anemia Globally | SNS Insider

Erythropoietin Drugs Market to reach USD 18.45 Bn by 2035, driven by chronic kidney disease, and increasing adoption of erythropoiesis-stimulating agents.
February 09, 2026 07:28 ET | Source: Arch Biopartners

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the...
January 28, 2026 00:35 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with...
January 13, 2026 11:15 ET | Source: Research and Markets

7MM Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease Market Opportunity Assessment and Forecasts 2024-2034

Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment and Forecast" report has been added to ...
December 11, 2025 08:08 ET | Source: Biomerica, Inc.

Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and...
December 01, 2025 10:47 ET | Source: Research and Markets

Chronic Kidney Disease Anemia Market Opportunity Assessment and Forecasts 2024-2034: Drug Costs, Safety Improvements, ESA Alternatives, and Enhanced Clinical Trial Design

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the...